|
1) Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010; 28: 275-80
|
|
|
|
2) Jain N, Reuben JM, Kantarjian H, et al. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer. 2009; 115: 3924-34
|
|
|
|
|
3) Rojas JM, Knight K, Wang L, et al. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007; 21: 2287-95
|
|
|
|
|
|
4) Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilmsʼ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004; 101: 13885-90
|
|
|
|
|
|
5) Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009; 113: 6541-8
|
|
|
|
|
|
6) Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood. 2010; 116: 171-9
|
|
|
|
|
|
7) Qazilbash MH, Thall PF, Wang X, et al. PR1 peptide vaccination for patients with myeloid leukemias. J Clin Oncol. 2007; 25(18) (Suppl): 7017
|
|
|
|
|
|
8) Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malig-nancies. Blood. 2008; 111: 236-42
|
|
|
|
|
|
9) Rezvani K, Yong AS, Mielke S, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8＋ T cells in myeloid malignancies. Haematologica. 2011; 96: 432-40
|
|
|
|
|
|
10) Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008; 111: 1357-65
|
|
|
|
|
|
11) Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelo-dysplastic syndrome and multiple myeloma. Haematologica. 2010; 95: 1191-7
|
|
|
|
|
|
12) Roddie H, Klammer M, Thomas C, et al. Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia. Br J Haematol. 2006; 133: 152-57
|
|
|
|
|
|
13) Kitawaki T, Kadowaki N, Fukunaga K, et al. A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate. Br J Haematol. 2011; 153: 796-9
|
|
|
|
|
|
14) Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilmsʼ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010; 107: 13824-9
|
|
|
|
|
|
15) Marijt E, Wafelman A, van der Hoorn M, et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation. Haematologica. 2007; 92: 72-80
|
|
|
|
|
|
16) Bornhäuser M, Thiede C, Platzbecker U, et al. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia. Blood. 2011; 117: 7174-84
|
|
|
|
|
|
17) Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8: 299-308
|
|
|
|
|
|
18) Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314: 126-9
|
|
|
|
|
|
19) Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009; 114: 535-46
|
|
|
|
|
|
20) Bendle GM, Linnemann C, Hooijkaas SI, et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med. 2010; 16: 565-70
|
|
|
|
|
|
21) Ochi T, Fujiwara H, Yasukawa M. Requisite considerations for successful adoptive immuno-therapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer. Expert Opin Biol Ther. 2011; 11: 699-713
|
|
|
|
|
|
22) Ahmadi M, King JW, Xue SA, et al. CD3 limits the efficacy of TCR gene therapy in vivo. Blood. 2011; 118: 3528-37
|
|
|
|
|
|
23) Okamoto S, Mineno J, Ikeda H, et al. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Res. 2009; 69: 9003-11
|
|
|
|
|
|
24) Ochi T, Fujiwara H, Okamoto S, et al. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked anti-leukemia reactivity and safety. Blood. 2011; 118: 1495-503
|
|
|
|
|
|
25) Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes. J Cancer. 2011; 2: 378-82
|
|
|
|
|
|
26) Kochenderfer JN, Feldman SA, Zhao Y, et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32: 689-702
|
|
|
|
|
|
27) Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010; 18: 843-51
|
|
|
|
|
|
28) Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363: 2511-21
|
|
|
|
|